Filing Analysis
OptimizeRx Corp announced a finance leadership succession plan involving the departure of Chief Financial & Strategy Officer Edward Stelmakh and the appointment of Andrew D’Silva as CFO and Heather Favazza as CAO, effective January 1, 2027.
🚩 Red Flags
- Significant severance package for departing CFO including a $247,500 lump sum bonus and continued salary/benefits.
- Potential change in control trigger: Stelmakh's agreement includes enhanced benefits if a change in control occurs during his advisory term.
📋 Key Facts
- Edward Stelmakh to step down as Chief Financial & Strategy Officer on December 31, 2026.
- Andrew D’Silva (currently CBO) appointed as CFO effective January 1, 2027; base salary $375,000 plus 50% target bonus.
- Heather Favazza (currently SVP, Corporate Controller) appointed as CAO effective January 1, 2027; base salary $325,000 plus 40% target bonus.
- Stelmakh to receive 12 months of base salary ($450,000/year), a lump sum bonus of $247,500, and COBRA coverage for 12 months.
- Stelmakh will serve as an advisor through December 31, 2027, with equity continuing to vest during the advisory term.
OptimizeRx Corp reported the results of its 2026 Annual Meeting of Shareholders held on June 9, 2026. Shareholders approved the election of directors, executive compensation, and an increase in the 2021 Equity Incentive Plan shares, but rejected a proposal to implement an evergreen provision for automatic share increases.
🚩 Red Flags
- Significant shareholder opposition to the evergreen provision, indicating a desire to limit future dilution.
📋 Key Facts
- Shareholders approved increasing the 2021 Equity Incentive Plan by 1,000,000 shares, bringing the total available to 5,450,000 shares.
- The proposal to adopt an 'evergreen provision' for automatic annual increases to the Equity Plan was rejected (5,627,324 For vs 7,001,699 Against).
- Grant Thornton, LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
- Seven directors were elected to the board.
- Executive compensation was approved on an advisory basis.
OptimizeRx Corporation announced the separation of Theresa Greco from her role as Chief Commercial Officer, effective June 15, 2026. Ms. Greco will transition into an advisory role for twelve months while receiving a significant severance package.
🚩 Red Flags
- Departure of a key executive (Chief Commercial Officer) responsible for revenue and market growth.
📋 Key Facts
- Theresa Greco's departure as Chief Commercial Officer is effective June 15, 2026.
- Severance includes continuation of $380,000 annual base salary for 12 months.
- A one-time lump sum cash bonus payment of $209,000 will be paid.
- COBRA premium reimbursements provided for 12 months.
- Ms. Greco will serve as an Advisor through June 15, 2027, allowing equity to continue vesting.
- Agreement includes a 12-month non-compete and non-solicitation clause.
OptimizeRx Corporation entered into a new $35 million senior secured credit facility with Fifth Third Bank to refinance existing debt and fund general corporate purposes, including potential stock repurchases. The new facility replaces an existing term loan with Blue Torch Finance, LLC and provides for a five-year maturity through May 2031.
🚩 Red Flags
- The filing contains multiple 8-K items (1.01, 1.02, 2.02, 2.03) in a single submission.
- The company is taking on $25 million in term debt with a first-priority security interest in substantially all assets.
📋 Key Facts
- The Credit Agreement provides for a $25.0 million term loan and a $10.0 million revolving credit facility.
- The facility matures on May 7, 2031, or earlier upon acceleration or prepayment.
- Interest rates are based on Term SOFR plus a margin of 1.75% to 2.50%, depending on leverage ratios.
- Proceeds were used to repay the existing debt with Blue Torch Finance, LLC in full.
- The agreement includes an uncommitted incremental accordion feature of up to $25.0 million.
- Financial covenants include a minimum fixed charge coverage ratio of 1.20 to 1.00 and a maximum total net leverage ratio of 2.75 to 1.00.
OptimizeRx Corporation (OPRX) has expanded its Board of Directors from six to seven members and appointed Mary Varghese Presti as an independent director, effective April 3, 2026. Ms. Presti will also serve on the Audit Committee as part of the company's ongoing board refreshment strategy.
📋 Key Facts
- Appointment of Mary Varghese Presti to the Board of Directors effective April 3, 2026.
- Board size increased from six to seven members to accommodate the appointment.
- Ms. Presti was appointed to the Audit Committee.
- Compensation includes an annual cash retainer of $45,000 and an annual equity grant valued at approximately $175,000.
- An additional $10,000 annual cash retainer is provided for Audit Committee service.
- The appointment is described as part of an 'ongoing process to refresh and expand' the Board.
OptimizeRx Corp dismissed its independent auditor, UHY LLP, and appointed Grant Thornton LLP as its new accounting firm. While no accounting disagreements were reported, the company disclosed a persistent material weakness in internal controls over financial reporting related to third-party data accuracy.
🚩 Red Flags
- Persistent material weakness in internal control over financial reporting (ICFR) identified in both 2024 and 2025 filings.
- Auditor change occurring while a material weakness remains unresolved.
📋 Key Facts
- Dismissed UHY LLP as the independent registered public accounting firm effective March 25, 2026.
- Appointed Grant Thornton LLP as the new auditor effective March 26, 2026.
- Audit reports for fiscal years ended December 31, 2025 and 2024 were unqualified.
- Disclosed a material weakness in internal control over financial reporting regarding the completeness and accuracy of data from third-party service organizations.
- The material weakness did not result in any restatements of financial statements.
OptimizeRx Corporation amended its financing agreement to extend its maturity date to 2029 and authorized a new $10 million share repurchase program. The company also reported its fourth quarter and full year 2025 financial results and provided 2026 guidance.
📋 Key Facts
- Entered into Amendment No. 4 to the Financing Agreement on March 2, 2026.
- Financing maturity date extended by two years to October 11, 2029.
- Board authorized a $10 million share repurchase program effective March 12, 2026, through March 15, 2027.
- The 1% applicable premium under the financing agreement was extended through October 11, 2027.
- Repurchases will be funded using available cash and cash equivalents.
OptimizeRx Corporation filed an 8-K to furnish its third quarter financial results for the period ended September 30, 2025. The filing serves as a formal announcement of the company's quarterly earnings via a press release.
📋 Key Facts
- Reporting date: November 6, 2025
- Period covered: Third quarter ended September 30, 2025
- The filing includes Exhibit 99.1 containing the official press release of financial results.
- Information under Item 2.02 is furnished but not filed for purposes of Section 18 liability.
OptimizeRx Corp announced leadership restructuring effective August 18, 2025. Brendan Merrell has been promoted to Chief Operating Officer, while Edward Stelmakh transitions from his dual CFO/COO role to a newly created position as Chief Financial & Strategic Officer.
🚩 Red Flags
- Internal reorganization/role changes can sometimes signal shifts in corporate strategy or internal friction, though not explicitly stated here.
📋 Key Facts
- Brendan Merrell appointed Chief Operating Officer (COO) effective August 18, 2025.
- Edward Stelmakh transitioned from CFO & COO to the new role of Chief Financial & Strategic Officer.
- Mr. Merrell's annual base salary is $325,000 with a target annual bonus of 40% of base salary.
- The restructuring involves an amended and restated employment letter for Mr. Merrell.
OptimizeRx Corporation filed an 8-K to furnish its second quarter financial results for the period ended June 30, 2025. The filing serves as a formal mechanism to provide the press release containing these earnings figures.
📋 Key Facts
- Report date: August 7, 2025
- Reporting period: Second quarter ended June 30, 2025
- The filing includes Exhibit 99.1 (Press Release) containing the financial results.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
OptimizeRx Corp announced that effective June 20, 2025, the Board of Directors increased its size to six members and appointed CEO Stephen Silvestro as a director.
📋 Key Facts
- Effective date of board change: June 20, 2025
- Board size increased from five to six members
- CEO Stephen Silvestro appointed to the Board
- Term for new director is until the 2026 annual meeting of stockholders or successor election
OptimizeRx Corporation held its 2025 Annual Meeting of Stockholders on June 11, 2025. The meeting resulted in the election of five directors and the ratification of UHY LLP as the independent auditor.
🚩 Red Flags
- High number of 'Votes Withheld' for director nominees (ranging from ~2M to ~5.6M votes), suggesting significant shareholder dissatisfaction with specific board candidates.
📋 Key Facts
- Annual Meeting held on June 11, 2025.
- Five directors were elected: Lynn O’Connor Vos, Catherine Klema, James Lang, Patrick Spangler, and Gregory D. Wasson.
- Executive officer compensation was approved on an advisory basis.
- UHY LLP was ratified as the independent registered public accounting firm for the 2025 fiscal year.
- On record date of April 29, 2025, there were 18,493,447 shares outstanding and entitled to vote.
OptimizeRx Corporation filed an 8-K to announce the release of its financial results for the first quarter ended March 31, 2025. The filing serves as a formal mechanism to furnish quarterly earnings information via a press release.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2025.
- Filing date: May 12, 2025.
- The financial results were announced via a press release dated May 12, 2025 (Exhibit 99.1).
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
OptimizeRx Corporation announced plans to add a new independent director in H2 2025 and confirmed that Whetstone Capital Advisors, LLC has withdrawn its notice of intent to nominate director candidates.
🚩 Red Flags
- Previous proxy contest/nomination threat from Whetstone Capital Advisors, LLC (though now withdrawn).
📋 Key Facts
- Company intends to add a new independent director to the board in the second half of 2025 as part of a board refreshment process.
- Whetstone Capital Advisors, LLC withdrew its March 6, 2025 notice regarding intent to nominate director candidates for the 2025 Annual Meeting.
- The withdrawal followed 'constructive engagement' between the Company and Whetstone.
OptimizeRx Corporation filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2024. The filing includes key performance indicators (KPIs) and provides initial guidance for the 2025 fiscal year.
📋 Key Facts
- Reported financial results for Q4 and Full Year ended December 31, 2024.
- Released Key Performance Indicators (KPIs).
- Provided initial guidance for the 2025 fiscal year.
- Filed via Item 2.02 (Results of Operations and Financial Condition).
OptimizeRx Corp announced the appointment of Stephen Silvestro as Chief Executive Officer, effective March 10, 2025. Mr. Silvestro transitions from his role as interim CEO to a permanent position following a tenure with the company since April 2019.
📋 Key Facts
- Stephen Silvestro appointed as CEO effective March 10, 2025.
- Silvestro previously served as President (Oct 2023–Jan 2025) and interim CEO (Jan 2025–Mar 2025).
- Annual base salary set at $500,000 with a target annual bonus of 80% of base salary.
- Includes a one-time equity grant valued at $1.0 million.
- Employment is on an at-will basis.
OptimizeRx Corp announced the departure of CEO William J. Febbo, effective December 31, 2024. The separation includes an advisory role through March 31, 2025, and a significant severance package.
🚩 Red Flags
- Significant cash outflow related to severance: $450k annual salary (for 18 months) + $450k lump sum bonus plus COBRA costs.
- CEO departure can signal internal instability or strategic shifts in micro-cap companies.
📋 Key Facts
- William J. Febbo stepped down as CEO and Board Member effective Dec 31, 2024.
- Separation Agreement includes 18 months of base salary at $450,000 per annum.
- A one-time lump sum payment of a $450,000 annual cash bonus target was triggered.
- Company will reimburse COBRA premiums for 12 months.
- Mr. Febbo will provide advisory services through March 31, 2025.
- Non-compete and non-solicitation covenants are in effect for 12 months.
OptimizeRx Corp announced the departure of CEO William J. Febbo, effective December 31, 2024. President Stephen Silvestro will serve as interim CEO starting January 1, 2025.
🚩 Red Flags
- Sudden departure of the Chief Executive Officer in late December.
- Uncertainty regarding the final compensation/terms of the departing CEO's separation agreement.
📋 Key Facts
- CEO William J. Febbo is stepping down from his roles as CEO and Board Member on December 31, 2024.
- Stephen Silvestro (current President) appointed as interim CEO and interim principal executive officer effective January 1, 2025.
- Febbo will provide transition advisory services through March 31, 2025.
- The Board has retained a search firm to find a permanent CEO successor.
- Details of the separation and advisory agreement for Febbo are yet to be finalized.
OptimizeRx Corporation filed an 8-K to furnish its third quarter financial results for the period ended September 30, 2024. The filing serves as a formal announcement of the earnings release issued on November 13, 2024.
📋 Key Facts
- Reporting Period: Third Quarter ended September 30, 2024
- Filing Date: November 13, 2024
- Event Type: Release of quarterly financial results (Item 2.02)
- Exhibit 99.1 contains the full press release regarding financial performance.
OptimizeRx Corporation filed an 8-K to announce the release of its financial results for the second quarter ended June 30, 2024. The filing serves as a formal notice that earnings data is being furnished via a press release.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2024.
- Filing date: August 8, 2024.
- The financial results were announced via a press release dated August 8, 2024 (Exhibit 99.1).
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
OptimizeRx Corporation held its 2024 Annual Meeting of Stockholders on June 5, 2024. Shareholders approved the election of six directors, executive compensation (advisory), an increase to the 2021 Equity Incentive Plan, and the ratification of UHY LLP as independent auditors.
🚩 Red Flags
- Increase in equity incentive plan (potential future dilution for existing shareholders).
📋 Key Facts
- The 2024 Annual Meeting was held on June 5, 2024.
- Stockholders approved increasing the shares available under the 2021 Equity Incentive Plan by 1,950,000 shares (totaling 4,450,000 shares).
- Six directors were elected to serve terms expiring at the next annual meeting.
- UHY LLP was ratified as the independent registered public accounting firm for fiscal year 2024.
- On the record date of April 11, 2024, there were 18,183,914 shares outstanding.
OptimizeRx Corporation filed an 8-K to furnish its quarterly earnings press release for the first quarter ended March 31, 2024. The filing serves as a formal announcement of financial results and does not contain substantive changes to corporate structure or material agreements.
📋 Key Facts
- Report date: May 14, 2024
- Reporting period: First quarter ended March 31, 2024
- The filing includes a press release as Exhibit 99.1 regarding financial results.
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
OptimizeRx Corp. issued an 8-K to announce its first quarter 2024 earnings call and provide preliminary unaudited revenue and adjusted EBITDA results for the period ended March 31, 2024.
📋 Key Facts
- Earnings call scheduled following the announcement of Q1 2024 preliminary results.
- Results are based on management estimates and are currently unaudited.
- The filing includes a press release (Exhibit 99.1) containing the preliminary financial data.
OptimizeRx Corporation issued an 8-K to furnish its financial results for the fourth quarter and full year ended December 31, 2023. The filing includes a press release detailing Key Performance Indicators (KPIs) and reiterates previously provided guidance for 2024.
📋 Key Facts
- Financial results released for Q4 and Full Year ended Dec 31, 2023.
- The company reiterated its initial financial guidance for the year 2024.
- Report includes Key Performance Indicators (KPIs) as part of the earnings announcement.
OptimizeRx Corp has entered into an amendment to its financing agreement to extend the deadline for delivering audited fiscal year 2023 financial statements from March 30, 2024, to April 15, 2024. The company also released preliminary, unaudited Q4 results and provided non-GAAP Adjusted EBITDA guidance.
🚩 Red Flags
- Delayed financial reporting: The extension of the audited financial statement deadline suggests potential difficulties in closing the books or audit complications.
- Inability to provide GAAP guidance: Management's inability to forecast GAAP metrics due to 'uncertainty and variability' indicates high volatility or lack of visibility into core expenses.
📋 Key Facts
- Amendment No. 1 to the Financing Agreement extends the Financial Reporting Due Date for FY2023 audited statements to April 15, 2024.
- The original deadline was March 30, 2024.
- Company held a conference call on March 28, 2024, to discuss preliminary, unaudited Q4 results.
- Management provided 2024 guidance for Adjusted EBITDA but is unable to provide GAAP-based guidance due to uncertainty in components like compensation and amortization.
OptimizeRx Corp. issued a press release reaffirming preliminary unaudited revenue and adjusted EBITDA results for fiscal year 2023 based on management estimates.
🚩 Red Flags
- Preliminary/unaudited nature of the reported financial metrics increases risk of future restatements if adjustments are required during final audit.
📋 Key Facts
- Reaffirmed preliminary, unaudited FY2023 revenue and adjusted EBITDA results as of March 11, 2024.
- Results are based on management estimates and are subject to final financial closing procedures.
- Independent registered public accounting firm has not audited or reviewed these preliminary figures.
OptimizeRx Corp announced significant changes to its Board of Directors effective January 24, 2024. This includes the retirement of Chairperson Gus Halas and the appointment of Lynn O’Connor Vos as the new Chairperson, alongside the addition of Catherine M. Klema to the Board.
🚩 Red Flags
- Departure of the Board Chairperson can sometimes signal internal friction, though no cause was stated here.
📋 Key Facts
- Gus Halas retired from his position as Chairperson of the Board effective January 24, 2024.
- Lynn O’Connor Vos appointed as Chairperson and member of Nominating & Governance, Compensation, and Audit Committees.
- Catherine M. Klema appointed to the Board, Audit Committee, and Compensation Committee.
- Board size increased from its previous count to seven (7) members.
- New director Catherine M. Klema compensation includes a $40,000 annual cash retainer and ~$150,000 in annual equity grants.
OptimizeRx Corporation filed an amendment to its 8-K to provide required financial statements and pro forma information following its merger with Medicx Health (Healthy Offers, Inc.). The filing includes audited and unaudited financial data for the acquired entity to satisfy SEC reporting requirements.
🚩 Red Flags
- The filing is an 'Amendment No. 1' specifically to provide missing financial information that was excluded in the original filing, which can sometimes indicate administrative delays or complexities in integrating acquired financials.
📋 Key Facts
- Consummated a merger with Healthy Offers, Inc. (d/b/a Medicx Health) on October 24, 2023.
- Medicx is now a wholly-owned subsidiary of OptimizeRx Corporation.
- Included audited balance sheets and income statements for Medicx as of Dec 31, 2022, and 2021.
- Included unaudited financial statements for Medicx as of June 30, 2023.
- Provided pro forma combined balance sheet (as of June 30, 2023) and condensed statement of operations (for six months ended June 30, 2023, and year ended Dec 31, 2022).
- Filed via an amendment (8-K/A) to provide previously omitted financial exhibits required under Item 9.01.